Zobrazeno 1 - 10
of 122
pro vyhledávání: '"Masaki Katayama"'
Autor:
Motomu Hashimoto, Wataru Yamamoto, Atsushi Kumanogoh, Yuichi Maeda, Yasutaka Okita, Ken Nakata, Shinya Hayashi, Masaki Katayama, Tadashi Okano, Takayuki Fujii, Seiji Okada, Kosuke Ebina, Yuki Etani, Makoto Hirao, Koichi Murata, Ryota Hara, Koji Nagai, Yuri Hiramatsu, Yonsu Son, Hideki Amuro, Takaichi Okano, Yo Ueda, Shotaro Tachibana
Publikováno v:
RMD Open, Vol 9, Iss 3 (2023)
Objectives This multicentre retrospective study in Japan aimed to assess the retention of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors (JAKi), and to clarify the factors affecting their retention in a real-world cohort
Externí odkaz:
https://doaj.org/article/c7789ed324f64b73b06d2a49de139a14
Autor:
Kosuke Ebina, Toru Hirano, Yuichi Maeda, Wataru Yamamoto, Motomu Hashimoto, Koichi Murata, Akira Onishi, Sadao Jinno, Ryota Hara, Yonsu Son, Hideki Amuro, Tohru Takeuchi, Ayaka Yoshikawa, Masaki Katayama, Keiichi Yamamoto, Yasutaka Okita, Makoto Hirao, Yuki Etani, Atsushi Kumanogoh, Seiji Okada, Ken Nakata
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract This multi-center, retrospective study aimed to clarify the factors affecting drug retention of the Janus kinase inhibitors (JAKi) including baricitinib (BAR) and tofacitinib (TOF) in patients with RA. Patients were as follows; females, 80.6
Externí odkaz:
https://doaj.org/article/4f5b37cb670c499a922ca1bc68f13735
Autor:
Sadao Jinno, Akira Onishi, Maureen Dubreuil, Motomu Hashimoto, Wataru Yamamoto, Koichi Murata, Tohru Takeuchi, Takuya Kotani, Yuichi Maeda, Kosuke Ebina, Yonsu Son, Hideki Amuro, Ryota Hara, Masaki Katayama, Jun Saegusa
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-9 (2021)
Abstract Background This multi-center, retrospective study aimed to clarify retention rates and reasons for discontinuation of either tumor necrosis factor inhibitors (TNFi) or interleukin-6 inhibitors (IL-6i) in patients with elderly-onset rheumatoi
Externí odkaz:
https://doaj.org/article/d2017bdb0d4045efb9549d25234a243b
Autor:
Hideyuki Shiba, Takuya Kotani, Koji Nagai, Kenichiro Hata, Wataru Yamamoto, Ayaka Yoshikawa, Yumiko Wada, Yuri Hiramatsu, Hidehiko Makino, Yo Ueda, Akira Onishi, Koichi Murata, Hideki Amuro, Yonsu Son, Ryota Hara, Toru Hirano, Kosuke Ebina, Masaki Katayama, Motomu Hashimoto, Tohru Takeuchi
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 8, p 7399 (2023)
This multicenter retrospective study aimed to clarify the prognostic factors for mortality and changes in treatment modalities and disease activities after the onset of Pneumocystis jirovecii pneumonia (PCP) in patients with rheumatoid arthritis (RA)
Externí odkaz:
https://doaj.org/article/294fe21088cc4b79aa53cd71ec5ba011
Autor:
Kosuke Ebina, Toru Hirano, Yuichi Maeda, Wataru Yamamoto, Motomu Hashimoto, Koichi Murata, Tohru Takeuchi, Hideyuki Shiba, Yonsu Son, Hideki Amuro, Akira Onishi, Kengo Akashi, Ryota Hara, Masaki Katayama, Keiichi Yamamoto, Atsushi Kumanogoh, Makoto Hirao
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-11 (2020)
Abstract Background This multi-center, retrospective study aimed to clarify retention rates and reasons for discontinuation of 7 biological disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib (TOF), one of the janus kinase inhibitors, in
Externí odkaz:
https://doaj.org/article/4669e0ad46c94ef0981d1d8a12dd9861
Autor:
Wataru Fukuda, Tadamasa Hanyu, Masaki Katayama, Shinichi Mizuki, Akitomo Okada, Masayuki Miyata, Yuichi Handa, Masatoshi Hayashi, Yoshinobu Koyama, Kaoru Arii, Toshiyuki Kitaori, Hiroyuki Hagiyama, Yoshinori Urushidani, Takahito Yamasaki, Yoshihiko Ikeno, Takeshi Suzuki, Atsushi Omoto, Toshifumi Sugitani, Satoshi Morita, Shigeko Inokuma
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-9 (2019)
Abstract Background The prophylaxis for hepatitis B virus (HBV) reactivation assumes that hepatic injury after reactivation is often rapidly progressive and can evoke fulminant hepatitis. The incidence and prognosis of reactivation in patients with r
Externí odkaz:
https://doaj.org/article/8d0fe31ff1e14bae8d6b4995c756ac2d
Autor:
Kosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, Toru Hirano, Ryota Hara, Masaki Katayama, Akira Onishi, Koji Nagai, Yonsu Son, Hideki Amuro, Keiichi Yamamoto, Yuichi Maeda, Koichi Murata, Sadao Jinno, Tohru Takeuchi, Makoto Hirao, Atsushi Kumanogoh, Hideki Yoshikawa
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-4 (2019)
Following publication of the original article [1], the authors noticed that two corrections were not implemented during the production process.
Externí odkaz:
https://doaj.org/article/a638623c16d5486fb66e1ce77e0ada0d
Autor:
Kosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, Toru Hirano, Ryota Hara, Masaki Katayama, Akira Onishi, Koji Nagai, Yonsu Son, Hideki Amuro, Keiichi Yamamoto, Yuichi Maeda, Koichi Murata, Sadao Jinno, Tohru Takeuchi, Makoto Hirao, Atsushi Kumanogoh, Hideki Yoshikawa
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
Abstract Background The aim of this study is to evaluate the retention rates and reasons for discontinuation for seven biological disease-modifying antirheumatic drugs (bDMARDs) in a real-world setting of patients with rheumatoid arthritis (RA). Meth
Externí odkaz:
https://doaj.org/article/8276c108654a42928fa6b40574c6e116
Autor:
Motomu Hashimoto, Moritoshi Furu, Wararu Yamamoto, Takanori Fujimura, Ryota Hara, Masaki Katayama, Akira Ohnishi, Kengo Akashi, Shuzo Yoshida, Koji Nagai, Yonsu Son, Hideki Amuro, Toru Hirano, Kosuke Ebina, Ryuji Uozumi, Hiromu Ito, Masao Tanaka, Koichiro Ohmura, Takao Fujii, Tsuneyo Mimori
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-10 (2018)
Abstract Background Clinical remission can be maintained after the discontinuation of biological disease-modifying antirheumatic drugs (bDMARDs) in some patients with rheumatoid arthritis (RA) (bDMARD-free remission (BFR)). It is unknown which bDMARD
Externí odkaz:
https://doaj.org/article/4cd5e2f3433e4dbcad326af2ee7761ea
Autor:
Kosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, Toru Hirano, Ryota Hara, Masaki Katayama, Akira Onishi, Koji Nagai, Yonsu Son, Hideki Amuro, Keiichi Yamamoto, Yuichi Maeda, Koichi Murata, Sadao Jinno, Tohru Takeuchi, Makoto Hirao, Atsushi Kumanogoh, Hideki Yoshikawa
Publikováno v:
PLoS ONE, Vol 14, Iss 5, p e0216624 (2019)
BackgroundThe aim of this study is to evaluate the retention rates and reasons for discontinuation for seven biological disease-modifying antirheumatic drugs (bDMARDs) in a real-world setting of elderly patients (65 years of age or older) with rheuma
Externí odkaz:
https://doaj.org/article/8c0d1d916a504071bbc6c6d78ba62932